Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald A Soff

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
The American Journal of Cardiology|May 28, 2017
Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active CancerEva S Laube, Anthony Yu, Dipti Gupta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2005
In vivo generation of angiostatin isoforms by administration of a plasminogen activator and a free sulfhydryl donor: a phase I study of an angiostatic cocktail of tissue plasminogen activator and mesnaGerald A Soff, Hao Wang, Deborah L Cundiff, et al.
Cancer Research|July 20, 2006
Differential binding of plasminogen, plasmin, and angiostatin4.5 to cell surface beta-actin: implications for cancer-mediated angiogenesisHao Wang, Jennifer A Doll, Keyi Jiang, et al.
Cancers|January 28, 2026
Romiplostim for Prevention of Severe Chemotherapy-Induced Thrombocytopenia in Lymphoma Patients-Phase I StudyErel Joffe, Zachary Epstein-Peterson, Lorenzo Falchi, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|May 29, 2020
Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI TrialAlok A Khorana, Mairéad G McNamara, Ajay K Kakkar, et al.
Cancer|October 13, 2011
Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancerAndrew S Epstein, Gerald A Soff, Marinela Capanu, et al.
American Journal of Obstetrics and Gynecology|March 7, 2015
Ovarian vein thrombosis after debulking surgery for ovarian cancer: epidemiology and clinical significanceSimon Mantha, Debra Sarasohn, Weining Ma, et al.
Journal of Thrombosis and Thrombolysis|October 4, 2016
Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort studySimon Mantha, Eva Laube, Yimei Miao, et al.
Pediatric Blood & Cancer|May 20, 2022
Chemotherapy-induced thrombocytopenia in pediatric oncology: Scope of the problem and opportunities for interventionMelanie D Degliuomini, Katherine Armstrong, Audrey Mauguen, et al.
Research and Practice in Thrombosis and Haemostasis|July 26, 2021
Rivaroxaban thromboprophylaxis for gastric/gastroesophageal junction tumors versus other tumors: A post hoc analysis of the randomized CASSINI trialJodi V Mones, Michael B Streiff, Alok A Khorana, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
The American Journal of Cardiology|May 28, 2017
Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active CancerEva S Laube, Anthony Yu, Dipti Gupta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2005
In vivo generation of angiostatin isoforms by administration of a plasminogen activator and a free sulfhydryl donor: a phase I study of an angiostatic cocktail of tissue plasminogen activator and mesnaGerald A Soff, Hao Wang, Deborah L Cundiff, et al.
Cancer Research|July 20, 2006
Differential binding of plasminogen, plasmin, and angiostatin4.5 to cell surface beta-actin: implications for cancer-mediated angiogenesisHao Wang, Jennifer A Doll, Keyi Jiang, et al.
Cancers|January 28, 2026
Romiplostim for Prevention of Severe Chemotherapy-Induced Thrombocytopenia in Lymphoma Patients-Phase I StudyErel Joffe, Zachary Epstein-Peterson, Lorenzo Falchi, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|May 29, 2020
Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI TrialAlok A Khorana, Mairéad G McNamara, Ajay K Kakkar, et al.
Cancer|October 13, 2011
Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancerAndrew S Epstein, Gerald A Soff, Marinela Capanu, et al.
American Journal of Obstetrics and Gynecology|March 7, 2015
Ovarian vein thrombosis after debulking surgery for ovarian cancer: epidemiology and clinical significanceSimon Mantha, Debra Sarasohn, Weining Ma, et al.
Journal of Thrombosis and Thrombolysis|October 4, 2016
Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort studySimon Mantha, Eva Laube, Yimei Miao, et al.
Pediatric Blood & Cancer|May 20, 2022
Chemotherapy-induced thrombocytopenia in pediatric oncology: Scope of the problem and opportunities for interventionMelanie D Degliuomini, Katherine Armstrong, Audrey Mauguen, et al.
Research and Practice in Thrombosis and Haemostasis|July 26, 2021
Rivaroxaban thromboprophylaxis for gastric/gastroesophageal junction tumors versus other tumors: A post hoc analysis of the randomized CASSINI trialJodi V Mones, Michael B Streiff, Alok A Khorana, et al.
Pageof 8